ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID

Trial Profile

ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs GSK 2696273 (Primary)
  • Indications Adenosine deaminase deficiency
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 30 May 2016 According to a MolMed media release, the European Commission approved GSK-2696273 (Strimvelis), the first ex-vivo stem cell gene therapy to treat patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID).
    • 27 May 2016 Primary endpoint (Survival) has been met, according to a GlaxoSmithKline media release.
    • 27 May 2016 Results published in a GlaxoSmithKline media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top